There have been few breakthroughs in the treatment of neurodegenerative disorders like Parkinson’s and Alzheimer’s disease potentially due to the selective targeting of single biological pathway.  The single “magic bullet” approach to disease management has limitations due to underlying multifactorial etiologies.1 For many diseases, concomitant pharmaceutical therapies (polypharmacy) are routinely employed to improve patient outcomes. Talon’s therapeutic approach combines multiple relevant mechanisms that minimally targets two disease pathways (Multi-Target drug approach)2 either through drug combination or by designing a single drug with multiple mechanisms of action (designed multiple ligand). Our multi-target approach is designed to provide more effective medicines with improved patient compliance and lower cost.  TPS-100 is a novel, multicomponent drug that has shown efficacy in improving gait function in disease models of Parkinsonism.


  1. Van der Schyf. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev. Clin Pharmacol. 4(3), 293-298 (2011)
  2. Makhoba XH, Viegas C Jr, Mosa RA, Viegas FPD, Pooe OJ. Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases. Drug Des Devel Ther. 14:3235-3249 (2020).